At its core, HB 1366 boils down to two words: Trust and transparency.

Last year in March, 50-State Network advocate Anna Marie Meyer testified before the Oregon House of Representatives Committee on Health Care in opposition to HB 2026.

The committee will discuss biologics license application (BLA) 125544, for CT-P13, a
proposed biosimilar to Janssen Biotech Inc.’s REMICADE (infliximab), submitted by Celltrion,
Inc.

Thank you Advocates! FDA Issues Draft Guidance for Biosimilar Naming: A Proposed Rule that Designates Official Names and Proper Names for Certain Biological Products Your efforts are making a difference. GHLF is pleased to share that the Food and Drug Administration (FDA) released a draft guidance requiring biological products licensed under the Public Health Service […]

GHLF applauds our CreakyJoints community for taking action!

Patient Advocate Cindi Brannum played a key role in the passing of Texas House Bill 751, which was signed into law by Governor Abbott on June 19th!

Patient advocates Kat Macfarlane and Candice Dusset were integral in the passing of Louisiana House Bill 319, which was signed into law on July 1st!

Victory number FIVE! Our Patient Advocate Regan submitted her testimony to North Carolina state government putting patient safety and transparency at the forefront of decision making.

Washington is the fourth state this year to pass a bill that notifies physicians when there patients’ medication has been substituted.

Our second advocacy victory of the year! CreakyJoints Patient Advocate Mariah recently shared her story before Colorado government and humanized an important patient safety concern.